INR) beyond that produced by a VKA alone. [6] [7] [8] Guidelines that allow the estimation of a valid INR under VKA treatment have been developed from clinical studies under combination treatment with argatroban. [8] [9] [10] The relationship between the false INR and the true INR has been shown to be dependent on the argatroban infusion rate and on the international sensitivity index of the PT reagent. 8, 9 Clinical practice and studies have shown that physicians transfer patients from argatroban to warfarin therapy with acceptably low complication rates, without overdosing or underdosing warfarin, and without major bleeding even when INRs are >5. 11 The purpose of this study was to show the preanalytical laboratory variable of assay interference associated with specimens obtained from DTItreated patients. Specifically, the effects of contamination of a blood specimen with a DTI on the quantitation of coagulation factors and inhibitors were evaluated.
D irect thrombin inhibitors (DTIs), such as the small-molecule argatroban, are the drug of choice for prophylaxis and treatment of thrombosis in patients with heparin-induced thrombocytopenia. [1] [2] [3] [4] [5] In many patients, however, longterm treatment with a vitamin K-antagonist (VKA) is indicated following the DTI treatment regimen. 5 It is known that argatroban prolongs the prothrombin time (PT) and the international normalized ratio Treatment with the thrombin inhibitor argatroban is often followed by vitamin K-antagonist treatment. In this study, the behavior of coagulation factors measured under these treatment regimens is shown. Healthy subjects received infusions of 1.0, 2.0, or 3.0 μg/kg/hr argatroban before and during phenprocoumon or acenocoumarol dosing. Quantitation of factors II, VII, IX, and X by clot-based assays resulted in dose dependent, approximately 20%, lower than expected values in the presence of argatroban. On the contrary, values for the inhibitors, protein C and protein S, were higher. Cotherapy exaggerated the effect by vitamin K-antagonist alone. However, testing by immunologic and chromogenic assays did not show any effect by argatroban. Coupled with a lack of bleeding in the subjects, these data suggests that argatroban does not affect coagulation proteins and that the observations are only an assay artifact. Assay interferences must be considered when measuring coagulation proteins in patients receiving thrombin inhibitors.
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Materials and Methods
Healthy subjects were treated with phenprocoumon (PC) or acenocoumarol (AC) alone and in combination with argatroban in a prospective, randomized, parallel group study design. 9 This clinical study was performed at the Pharmazentrum Frankfurt, Institute for Clinical Pharmacology, University Hospital, Frankfurt, Germany. After approval by the local institutional review board and obtaining written informed consent, male volunteers (N = 39; age range = 22-41 years; weight = 61-98 kg; normal PT, activated partial thromboplastin time [aPTT] , and von Willebrand factor antigen) were enrolled. None of the volunteers had taken drugs or medications during the 14 days prior to the study.
Six subjects were randomized to 1 of 6 treatment groups receiving either standard dose of PC (Ratiopharm GmbH, Ulm, Germany) or AC (Novartis Pharma, Rueil Malmaison, France) as VKA and argatroban (Mitsubishi Pharma Corporation, Tokyo, Japan) at 1 of 3 different dose levels. To ensure 6 subjects with at least 2 full days of data out of days 3, 4, and 5 per treatment group, 3 subjects who were withdrawn during the study (2 subjects withdrawn before day 4 because of an acute viral infection and 1 subject excluded due to a predefined INR cutoff of >3.5 days before start of the argatroban infusion) were complemented by 3 further subjects.
Subjects received an intravenous infusion of 1.0, 2.0, or 3.0 μg/kg/min argatroban for 5 hours on 4 occasions always on the same dosing regimen (days 1, 3, 4, and 5). Oral anticoagulants were dosed to reach a therapeutic anticoagulation level (INR 2-3) as follows: 9 mg PC or 8 mg AC 4 hours after completion of the first infusion of argatroban on day 1; day 2 (morning) 9 mg PC or 4 mg AC; days 3 and 4 (morning) before the infusion of argatroban 1.5 to 6 mg PC or 2 to 8 mg AC depending on the predose INR.
Blood samples were collected on days 1 (no VKA, argatroban only), 3 (initiation phase of VKA), and 5 (near steady state of VKA). Specimens were obtained at 0 (immediately before start of the argatroban infusion), 1, 4, and 5 hours (under argatroban), and at 7 and 9 hours (2 and 4 hours after termination of the argatroban infusion). Blood was also collected on day 2 at 0 hour (19 hours after termination of the argatroban infusion). The half-life of argatroban is 40 to 50 minutes. 2 Steady-state kinetics is reached in 1 to 3 hours after the start of the infusion, and at therapeutic levels, anticoagulation parameters generally return to baseline 2 to 4 hours after discontinuation of argatroban. 10 Venous blood was collected into 3.2% sodium citrate using a catheter inserted into a cubital vein, immediately centrifuged at 2000 g for 10 minutes to obtain platelet poor plasma, then frozen (−70°C). Frozen plasmas were shipped on dry ice for overnight delivery to the Cardiovascular Institute at Loyola University Chicago, Maywood, Illinois, for testing.
Laboratory personnel were blinded to the treatment allocation and clinical data. Clot-based assays for coagulation factors II, VII, IX, and X were performed on the STA Compact coagulation analyzer using PT, aPTT, and factor-deficient plasmas for use on the STA (Diagnostica Stago, Asnieres, France); protein C and protein S levels were determined by the StaClot assays (Diagnostica Stago) on the STA Compact. Factor X activity levels were also determined using the amidolytic assay from DiaPharma (West Chester, Ohio) on the ACL (Beckman Coulter/ Instrumentation Laboratory, Miami, Florida) coagulation analyzer. Factor VII and factor IX antigen levels were determined by the Asserachrom immunologic enzyme-linked immunosorbent assays (Diagnostica Stago). Assay controls and calibrators were used according to the manufacturers' recommendations, and standard quality assurance practices in the laboratory were followed. The reproducibility of each assay is <10% variation.
Argatroban concentration levels were determined on another set of frozen plasma samples (−20°C) shipped to Mitsubishi Kagaku Bio-Clinical Laboratories Inc, Tokyo, from the clinical study site. These samples were analyzed by a liquid chromatography tandem mass spectrometry (LC-MS/MS) assay. Pharmacokinetic parameters were calculated by the NonLin program.
Statistical analysis and tabulation were performed using SAS version 8.2. The statistical methods used were the 2-way ANOVA model (using SAS PROC GLM) with factors of argatroban dose, day and time, and type of VKA.
Results
Coagulation Factor (Activators)
Clot-based assays. As illustrated for factor X, values for coagulation factors measured by clot-based assays were decreased in the presence of argatroban alone (0-5 hours, day 1; Figure 1 ). Expected decreases in vitamin K-dependent coagulation factor levels were observed over the 5-day VKA treatment period. Under combined argatroban and VKA therapy (0-5 hours, days 3 and 5), measured factor levels were lower than for VKA monotherapy (7-24 hours, days 3 and 5). The cotherapy response was dose dependent for argatroban, and time dependent for PC and AC. There was no difference in the results obtained with PC and AC.
The values obtained for coagulation factor measurements were analyzed by linear regression comparing VKA monotherapy and cotherapy of VKA plus argatroban. For treatment days 1, 3, and 5, selected data pairs for analysis from the same individual included factor levels on VKA alone (x-axis) versus factor levels on VKA plus argatroban (y-axis). Two data pairs per day corresponded to blood samples collected at times 0 versus 4 hours and 9 versus 5 hours.
Linear regression scatter plots of the data for the clotting activities of factors VII, IX, and X are shown in Figures 2A-2C , respectively. For each coagulation factor, the data points fell below the line of unity, indicating that VKA therapy combined with argatroban therapy, compared with VKA monotherapy, results in lower than expected factor levels when measured using clot-based assays. Analysis of factor II by clot-based assay produced the same finding. Cotherapy with AC and argatroban showed the same effect as cotherapy with PC.
The additive reduction in the coagulation factor level correlated with the circulating concentration of argatroban as determined by high-performance liquid chromatography and aPTT, and it paralleled the effect of argatroban circulating concentration on the INR. 9 Mean (standard deviation) maximal plasma concentrations of argatroban on cotherapy with a VKA ranged from 278 ± 247 to 491 ± 121 ng/mL depending on dose. Four hours after discontinuation of the argatroban infusion (at 9 hours), mean plasma levels declined to <10 ng/mL (<20 ng/mL for the highest dose), where no aPTT anticoagulant effect was exerted.
Immunologic or chromogenic assay. As assessed by linear regression analysis, coagulation factor levels were the same for both VKA monotherapy and combined VKA plus argatroban therapy specimens when measured by nonclot-based, immunologic (factors VII and IX; Figures 3A and 3B ) or chromogenic (factor X; Figure 3C ) assay. The data points clustered around the line of unity.
There tended to be a wider variation in the data for factor VII by immunologic assay and factor X by chromogenic assay; however, the patterns were consistent in all individuals with decreased levels due to VKA therapies. The data for factor IX by immunologic assay is limited because this analysis was only performed in 2 randomly selected subjects per group on days 1 and 5. There was no difference between the results for PC and AC cotherapy with argatroban in these determinations.
Coagulation Factor (Inhibitors)
Contrary to the coagulation factor data above, values for the coagulation inhibitor protein C measured by a clot-based assay were increased in the presence of argatroban (0-5 hours, day 1; Figure 4 ). The expected decrease in activity by VKA treatment was observed over the 5-day treatment period. However, when VKA therapy was combined with argatroban therapy the factor levels measured were higher (0-5 hours, days 3 and 5) than for VKA monotherapy (7-24 hours, days 3 and 5). The cotherapy response was dose dependent for argatroban and time dependent for the VKA therapy. The same results were obtained for protein S. There was no difference in the results obtained with PC and AC. The values obtained for protein C ( Figure 5A ) and protein S ( Figure 5B ) measured by clot-based assays and analyzed by linear regression analysis showed high levels for cotherapy of VKA plus argatroban than for VKA monotherapy (ie, the data plotted above the line of unity). The protein S clot-based assay was more sensitive to this effect than the clotbased protein C assay. There was no difference in the results obtained for PC and AC.
Overall
The effect of argatroban was observed with each individual coagulation protein measurement; however, results varied by assay (Table 1) . Consistently there was a further effect with higher doses of argatroban. For factors II, VII, and X determined by clot-based assay there was an approximate 15% decrease in the obtained factor value with 1 μg/kg/min argatroban, a 20% decrease with 2 μg/kg/min, and a 30% decrease with 3 μg/kg/min. Argatroban dose-dependent responses for factor IX, protein C, and protein S clot-based assays were more marked. The immunologic and chromogenic assays, however, showed only normal assay variation without an effect by argatroban.
Discussion
The study we report here is a sister study of the clinical study conducted by Harder et al 9 that determined the effect of argatroban on the INR to establish a guideline for monitoring the VKAs, PC and AC, administered with argatroban treatment. The study was designed to obtain data exclusively related to the DTI, the VKA, and the coadministration of both drugs.
Our study showed that in the presence of argatroban, results of coagulation factor quantitation are lower than actual levels when using clot-based assays. Specifically, for coagulation factors measured in association with VKA therapy, there is a perceived additive reduction of the coagulation factor level with argatroban cotherapy. The argatroban effect on coagulation factor level measurement, however, is not observed when chromogenic assays are used. Secondly, our study showed that in the presence of argatroban, measured levels of inhibitors of the coagulation system are higher than actual levels when clot-based assays are used. Specifically, the decrease of protein C and protein S caused by VKA treatment are underestimated if argatroban is present in the patient's test specimen. Again the argatroban effect on the measurement of these inhibitors is not observed when immunologic assays are used.
The observed effects with argatroban were dose dependent and occurred with all clot-based factor assays, but were not reflected in any nonclot-based assay. The data of this study is consistent with and validates our earlier finding that argatroban exerts no effect on coagulation proteins, 6 and that this observation is only assay interference. Additional evidence to support this conclusion comes from the clinical data of this study as reported by Harder et al 9 in which there was no clinical bleeding or other safety issue observed with argatroban and VKA cotherapy nor were there unexpected results in the bleeding time test of the study subjects.
The reason for this artifact on the measurement of coagulation factors and inhibitors lies within the principle of clot-based analytical assays. The fibrin clot formed as the end point of the assay is mediated by thrombin generated during activation of the coagulation system. Free argatroban in plasma reacts with the generated thrombin causing the typical response seen in coagulation laboratories when an inhibitor is present in the patient plasma sample (decreased quantitation of coagulation activators and increased quantitation of coagulation inhibitors). Because functional thrombin is common to all assays that use clotting as an end point, it is not surprising that all clot-based assays are affected in the presence of an external inhibitor such as a DTI. Assays that are not dependent on the coagulation cascade and a fibrin end point eliminate the interference of the DTI.
Although not tested, it is assumed that the same assay artifact will be observed for all DTIs. This is based on the demonstrated prolongation of the PT/INR, aPTT, and activated clotting time by napsagatran, melagatran, bivalirudin, and high concentrations of lepirudin. [12] [13] [14] [15] [16] Factor IX and protein S clot-based assays were more sensitive to the argatroban effect. This is related neither to the half-life of the coagulation proteins under VKA treatment (half-life of factor VII < protein C < factor IX < protein S < factor X < factor II) nor to the type of VKA because the relationship between argatroban and PC or AC was similar to the relationship between argatroban and warfarin. 6, 17 The enhanced sensitivity in the factor IX and protein S assays could be related to reagent sensitivity such as seen for the INR [7] [8] [9] or due to the fact that both coagulation proteins act as cofactors in the coagulation system and not as the primary active protein. 
